CLOV Stock Risk & Deep Value Analysis
Clover Health Investments Corp
DVR Score
out of 10
What You Need to Know About CLOV Stock
We analyzed Clover Health Investments Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CLOV through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
Get notified when CLOV moves
Same alert types as Telegram — presets or custom thresholds in your 🔔 feed.
📈CLOV Performance Overview3yr weekly
Unlock CLOV Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
CLOV Risk Analysis & Red Flags
What Could Go Wrong
A key risk is that the proven MCR improvements from Clover Assistant (8-20%) do not scale across a much larger membership base or that larger incumbents develop equally effective or superior proprietary tech. If Clover Assistant's effectiveness plateaus or is surpassed, the company's primary competitive differentiator for cost efficiency could be eroded, hindering sustained profitability and growth, especially given the intense competition in the MA market.
Risk Matrix
Overall
Aggressive
Financial
Medium
Market
Medium
Competitive
High
Execution
Medium
Regulatory
High
Red Flags
- ⚠
Insider Selling: CEO of Home Care sold 175,000 shares in March 2026; 5 insider sales vs. 0 purchases in the last 6 months, suggesting potential lack of conviction from some insiders.
- ⚠
Analyst Price Targets: Median analyst target of $2.90 is below the current stock price of $3.59, indicating that current market valuation may already exceed analyst expectations despite positive Q1 results.
Upcoming Risk Events
- 📅
Q2 2026 Earnings Miss (estimated early August 2026): If Q2 revenue or net income falls below Q1 2026 levels or misses consensus, indicating a lack of sustained profitability.
- 📅
Regulatory Changes to MA Reimbursement (Ongoing FY2026-FY2027): Any significant negative adjustments by CMS to Medicare Advantage risk adjustment or quality bonus programs, potentially impacting premium revenue and profitability by 5-10%.
When to Reconsider
- 🚪
Exit if quarterly revenue growth decelerates to below 20% YoY for two consecutive quarters, indicating a loss of growth momentum from the current 62.0% YoY.
- 🚪
Sell if the Insurance Benefits Expense Ratio consistently rises above 90% for two consecutive quarters, suggesting deteriorating medical cost management after Q1 2026's 86.5%.
Unlock CLOV Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
If Clover Health can continue to scale MA membership by ~20-30% annually while its Clover Assistant technology consistently drives 15-20% MCR improvement for members in year 2-4, then the company could achieve sustained high-single-digit net margins on an accelerating revenue base, justifying a P/S multiple expansion to 1.5x-2.0x on ~$5-7B revenue within 3-5 years, potentially leading to a market cap of $7.5-14B (a 4-7x return from current levels). This is bullish because the Q1 2026 results (profitability, strong growth, validated MCR impact) indicate a pivotal turnaround that the market has not fully priced into its current valuation or analyst targets.
Is CLOV Stock Undervalued?
Unlock the full AI analysis for CLOV
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CLOV Price Targets & Strategy
12-Month Target
$8.50
Bull Case
$12.00
Bear Case
$2.50
Valuation Basis
1.5x P/S multiple applied to projected FY2026 revenue of ~$3.0B, reflecting strong growth and recent profitability.
Entry Strategy
Dollar-cost average between current price ($3.59) and $3.00, targeting dips as market absorbs recent earnings and re-evaluates.
Exit Strategy
Consider taking initial profits at $8.00-$9.00; re-evaluate above $12.00 for further upside. Stop loss at $2.50 to protect capital if positive momentum falters.
Portfolio Allocation
7% for aggressive risk tolerance due to small-cap nature and turnaround phase.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is CLOV Financially Healthy?
Valuation
P/E Ratio
-20.40
PEG Ratio
-0.10
Price/Sales
0.80
Profitability
Gross Margin
15.20%
Operating Margin
-4.44%
Net Margin
-4.45%
Return on Equity
-25.73%
Revenue Growth
40.34%
EPS
$-0.17
Balance Sheet
Current Ratio
1.60
Quick Ratio
1.54
Cash & Equivalents
$418.20M
Cash Flow
Operating Cash Flow
$107.90M
EBITDA
$40.30M
Other
Beta (Volatility)
2.43
Does CLOV Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat is strengthening as Clover Assistant demonstrates quantifiable cost-saving benefits and fosters deeper physician integration. Its durability depends on continued innovation to stay ahead of larger competitors' R&D efforts and the ability to scale adoption to critical mass, making it a standard for participating physicians.
Moat Erosion Risks
- •Competitor Replication: Larger, well-funded competitors like UnitedHealth or Humana could develop similar or superior AI-driven physician support tools.
- •Limited Physician Adoption: Inability to significantly expand the use of Clover Assistant across a broader network of physicians and health systems.
CLOV Competitive Moat Analysis
Sign up to see competitive advantages
CLOV Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral-Bullish (Retail investors may be optimistic about the recent profitability turnaround, but the EPS miss and analyst targets could temper enthusiasm).
Institutional Sentiment
Neutral (Mixed analyst ratings of 1 Buy, 3 Hold, 1 Sell, with median price targets below current price, suggesting a cautious institutional stance despite the positive Q1 results).
Insider Activity (Form 4)
Brady Patrick Priest, CEO of Home Care, sold 175,000 shares for an estimated $379,750 on March 4, 2026. In the last 6 months, there have been 5 insider sales and 0 insider purchases.
Options Flow
Normal options activity (No specific unusual activity or put/call ratio direction provided in the research).
Earnings Intelligence
Next Earnings
Estimated early August 2026 (for Q2 2026 results)
Surprise Probability
Medium (Recent Q1 2026 showed a significant revenue beat but an EPS miss, indicating potential for mixed results and volatility around expectations).
Historical Earnings Pattern
With Q1 2026 being the first profitable quarter following a turnaround, historical patterns are less indicative. The stock's reaction to future earnings will likely be highly sensitive to sustained profitability and growth metrics.
Key Metrics to Watch
Competitive Position
Top Competitor
UnitedHealth (UNH)
Market Share Trend
Gaining (average MA membership increased to 154,607 in Q1 2026, indicating organic growth, though from a small base compared to incumbents).
Valuation vs Peers
Clover Health, with an annualized P/S of approximately 0.6x (based on Q1 2026 revenue and current market cap), trades at a discount to larger, more established managed care peers like UnitedHealth (P/S ~1.5x) but is competitive with other pure-play MA providers (0.5-0.8x P/S), despite its much higher growth rate, suggesting potential for multiple expansion if profitability sustains.
Competitive Advantages
- •Clover Assistant: Proprietary AI-driven platform for physicians, demonstrated to improve MCR by 8-20% over 1-4 years.
- •Physician Engagement Model: Focus on empowering primary care physicians with data for proactive patient care, fostering stronger provider relationships.
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive CLOV Stock Higher?
Near-Term (0-6 months)
- •Q2 2026 Earnings Report (estimated early August 2026): Continued positive net income and sustained >40% YoY revenue growth.
- •Increased Clover Assistant Adoption (Q2-Q3 2026): A 5-10% increase in MA members actively engaging with Clover Assistant, signaling successful scaling of the technology.
Medium-Term (6-18 months)
- •Geographic/Plan Expansion (FY2027): Announcement of entry into 2-3 new Medicare Advantage service areas or successful launch of new plan types, contributing an estimated 10-15% to new member growth.
- •Partnership with larger payer (Late 2027): Successful pilot or commercial agreement to license Clover Assistant to another managed care organization, signaling broader market validation beyond Clover's own plans, potentially adding a new revenue stream.
Long-Term (18+ months)
- •Clover Assistant as a Standalone Platform (FY2028-FY2029): If Clover Assistant becomes a widely adopted SaaS solution by other insurers, enabling diversified revenue streams and potential re-rating as a health tech company rather than solely an MA insurer.
- •Sustained Market Share Gains (FY2029-FY2031): Achieving 2-3% market share in key MA markets (e.g., California, Florida, Texas), driving annual revenue beyond $10B with consistent ~5% net margins.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for CLOV?
- ✓
Quarterly MA membership growth: Monitor for sustained >15% YoY growth in each subsequent quarter.
- ✓
Insurance Benefits Expense Ratio: Watch for consistent improvement or maintenance below 88% in Q2 2026 and beyond, validating Clover Assistant's cost-saving impact.
- ✓
Q2 2026 Net Income: Ensure it remains positive and ideally grows sequentially from Q1 2026's $27.3 million.
Bull Case Analysis
Sign up free to see the bull case
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Clover Health Investments Corp Makes Money
Clover Health is a technology-driven health insurance company primarily operating in the Medicare Advantage (MA) market. It offers MA plans to eligible individuals and manages their healthcare, aiming to improve health outcomes and reduce costs through its proprietary AI platform, Clover Assistant. This platform provides physicians with real-time data and insights to better manage patient care and proactively address health risks. The company makes money by collecting premiums from its MA members, and its profitability depends on effectively managing medical costs (MCR) through its technology.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Clover Health Investments Corp (CLOV)?
As of May 21, 2026, Clover Health Investments Corp has a DVR Score of 6.3 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Clover Health Investments Corp?
Clover Health Investments Corp's market capitalization is approximately $1.8B..
What is the risk level for CLOV stock?
Our analysis rates Clover Health Investments Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CLOV?
Clover Health Investments Corp currently has a price-to-earnings (P/E) ratio of -20.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Clover Health Investments Corp's revenue growing?
Clover Health Investments Corp has reported revenue growth of 40.3%. The company is showing strong top-line momentum.
Is CLOV stock profitable?
Clover Health Investments Corp has a profit margin of -4.5%. The company is currently unprofitable.
How often is the CLOV DVR analysis updated?
Our AI-powered analysis of Clover Health Investments Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CLOV (Clover Health Investments Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.